Ventyx Biosciences Proposed Sale to Eli Lilly Under Investigation by Kahn Swick & Foti for Adequacy of Price and Process.
ByAinvest
Thursday, Feb 5, 2026 5:30 pm ET1min read
LLY--
VTYX--
Kahn Swick & Foti, LLC is investigating the proposed sale of Ventyx Biosciences to Eli Lilly and Company, with shareholders set to receive $14.00 in cash per share. The firm is seeking to determine if the consideration is adequate and if the process leading to it undervalues the company. If you believe the transaction undervalues Ventyx, you can contact KSF for more information without obligation or cost.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet